Ongoing Prospective Multicenter Safety Study of the Cytoprotectant Amifostine Given Subcutaneously: Overview of Trial Design

Michael A. Samuels, Isagani M. Chico, Robert L. Hirsch, Keri Fullmer

Research output: Contribution to journalArticle

2 Scopus citations


The study is a prospective, open-label, multicenter safety study designed to identify treatment-related side effects of amifostine (Ethyol, WR-2721; MedImmune, Inc, Gaithersburg, MD) administered as a subcutaneous injection for the prevention of radiation-induced toxicities. More than 100 patients (68 males, 33 females; median age, 64 years) received 500 mg of amifostine by subcutaneous injection before daily radiation therapy. Four types of targeted adverse events were examined as to their occurrence and possible relationship with amifostine. These adverse events included nausea/vomiting, local skin reactions, skin rashes, and hypotension.

Original languageEnglish (US)
Pages (from-to)94-95
Number of pages2
JournalSeminars in Oncology
Issue number6 SUPPL. 18
StatePublished - Dec 2003


ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this